S-1: Nexalin Technology Files S-1 for Resale of Common Stock

Nexalin Technology has filed an S-1 registration statement for the resale of up to 2,798,613 shares of common stock by selling stockholders, primarily related to warrants issued in connection with their 2022 public offering.

Summary

• Nexalin Technology has filed an S-1 registration statement to allow certain stockholders to resell up to 2,798,613 shares of common stock.
• These shares are primarily related to warrants issued during the company's 2022 initial public offering and shares issued to Maxim Partners for services.
• The company will not receive any proceeds from the sale of these shares, but may receive proceeds if the warrants are exercised for cash.
• The warrants are immediately exercisable and expire three years from the date of issuance on September 16, 2022.
• The company is an emerging growth company and has elected to comply with certain reduced public company reporting requirements.
• Nexalin is focused on developing neurostimulation products to treat mental health conditions such as anxiety, insomnia, and depression.
• The company's Gen-1 devices are currently classified as Class II devices for anxiety and insomnia, requiring a new 510(k) application for marketing approval.
• The company is developing Gen-2 and Gen-3 devices with a new 15 milliamp waveform, which they believe will enhance patient response.
• A new PMA application is in strategic development for the treatment of depression utilizing both Gen-2 and Gen-3 devices.
• The company has a joint venture in China for the clinical development, marketing, sale and distribution of their Gen-2 devices.
• The company's Gen-2 device has been approved in China for the treatment of insomnia and depression.
• The company has received regulatory approval for their Gen-2 device in Brazil and conditional approval in Oman.
• The company is developing a virtual clinic platform to allow physicians to diagnose and prescribe their Gen-3 headset for home use.
• The company is also exploring the use of their technology for substance use disorders, chronic pain, and Alzheimers disease.

Sentiment

Score: 6

Explanation: The document presents a mix of positive developments, such as regulatory approvals and technology advancements, alongside risks and challenges, including potential dilution and regulatory hurdles. The sentiment is cautiously optimistic, reflecting the potential of the technology but also the uncertainties of the business.

Positives

• The company is developing advanced neurostimulation technology with a new 15 milliamp waveform.
• The company has a joint venture in China, which has already approved the Gen-2 device for insomnia and depression.
• The company has received regulatory approvals in Brazil and conditional approval in Oman.
• The company is developing a virtual clinic platform to expand access to their technology.
• The company is exploring the use of their technology for various mental health conditions and other disorders.
• The company has a supplier quality agreement with Velentium to ensure quality assurance of their products.

Negatives

• The company will not receive any proceeds from the resale of shares by the selling stockholders.
• The company's Gen-1 devices require a new 510(k) application for marketing approval for anxiety and insomnia.
• The company's treatment of depression with their devices requires a full PMA from the FDA.
• The company is subject to regulatory, liquidity, and enforcement risks in China due to their joint venture.
• The company is an emerging growth company and has elected to comply with certain reduced public company reporting requirements.
• The company has identified certain material weaknesses in their internal controls.

Risks

• The selling stockholders may choose to sell the shares at prices below the current market price.
• A large number of shares of common stock may be sold in the market following this offering, which may significantly depress the market price of the common stock.
• The company may not be able to comply with the applicable continued listing requirements of The Nasdaq Stock Market.
• The trading price of the company's common stock may be volatile.
• The company will have broad discretion as to the proceeds that they receive from the cash exercise by any holder of the Warrants.
• The company may experience future dilution as a result of issuance of the Shares, future equity offerings and other issuances of common stock or other securities.
• The company does not intend to pay cash dividends on their common stock in the foreseeable future.
• Concentration of ownership of the company's common stock among existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.
• Provisions in the company's corporate charter documents and under Delaware law could make an acquisition of the company more difficult.
• The company is an emerging growth company and as a result of the reduced disclosure and governance requirements applicable to emerging growth companies, their common stock may be less attractive to investors.
• The company has identified certain material weaknesses in their internal controls, which could impair their ability to produce accurate consolidated financial statements on a timely basis.

Future Outlook

The company plans to conduct decentralized clinical trials for the Gen-3 device in the U.S. and continue to consult with the FDA. They intend to extend the development and commercialization of their devices for sale in the U.S. and other territories, given the potential unmet demand for the treatment of mental health conditions. They also plan to develop a strategic schedule to execute additional pilot trials and/or pivotal trials for the new Gen-3 device for anxiety and insomnia in the United States, Brazil and China beginning in the first quarter of 2025.

Management Comments

• The Nexalin research team believes that the new 15 milliamp Gen-2 and Gen-3 devices can penetrate deeper into the brain and stimulate associated structures that contribute to or cause mental illness, which we believe will generate enhanced patient response without any risk or unpleasant side effects.
• Our mission is to remove the stigma of expensive psychotherapy or pharmaceuticals with the attendant side effects and dependency issues and replace such stigma with clinically proven and cost-effective technology that is easily accessible in the privacy of the patients home and monitored by licensed healthcare providers.

Industry Context

The document highlights the growing market for non-pharmaceutical treatments for mental health conditions, including anxiety, insomnia, and depression. It positions Nexalin's technology as a potential disruptor in the traditional mental health treatment model, offering a cost-effective and efficient alternative to medications and psychotherapy. The document also notes the increasing interest in home-based care and the potential for virtual clinics to expand access to treatment.

Comparison to Industry Standards

• The document positions Nexalin's technology as a potential alternative to traditional treatments like pharmaceuticals, ECT, and TMS.
• Unlike pharmaceuticals, Nexalin's devices aim to avoid side effects and dependency issues.
• Compared to ECT, Nexalin's technology is non-invasive.
• Compared to TMS, Nexalin's technology is designed to be more cost-effective and easier to administer.
• The document mentions that some existing neurostimulation products are either high risk, high cost, difficult to administer, or invasive, which Nexalin aims to address with its technology.
• The company's focus on a virtual clinic model aligns with the trend of increasing telehealth adoption.

Related Party Transactions

• The document mentions a joint venture with Wider Come Limited, a related party, for the clinical development, marketing, sale and distribution of Nexalin's Gen-2 devices in China and other countries in the region.
• Wider is obligated to fund all operations for the initial 12-month period of the Joint Venture, after which Nexalin and Wider plan to jointly fund the Joint Ventures operating expenses in accordance with their pro rata ownership.
• The company issued 331,818 shares of common stock to Wider and affiliates of Wider in 2024, in satisfaction of obligations pursuant to their collaborative agreement and their continuing research and development efforts.

Stakeholder Impact

• Shareholders may experience dilution from the resale of shares and potential future equity offerings.
• Employees may benefit from the company's growth and expansion.
• Customers (patients) may benefit from access to new and innovative treatments for mental health conditions.
• Suppliers may benefit from increased demand for the company's products.
• Creditors may be impacted by the company's financial performance and ability to repay debts.

Next Steps

• The company plans to conduct decentralized clinical trials for the Gen-3 device in the U.S.
• The company plans to file a new PMA for the treatment of depression with the Gen-2 and Gen-3 devices.
• The company plans to develop a strategic schedule to execute additional pilot trials and/or pivotal trials for the new Gen-3 device for anxiety and insomnia in the United States, Brazil and China beginning in the first quarter of 2025.
• The company plans to launch a virtual clinic platform.
• The company plans to continue research and development for other treatment indications, including substance use disorder, TBI, PTSD, Alzheimers disease, and dementia.

Key Dates

Keywords

neurostimulation, mental health, anxiety, insomnia, depression, FDA, PMA, 510(k), tACS, China, virtual clinic, warrants, common stock, resale, emerging growth company